#NanoVaccine
LightNews LightNews
robedwards1.bsky.social
Nanovaccine halts tumor growth and reduces cancer recurrence in lab models

phys.org/news/2025-09... via @physorg_com
Nanovaccine halts tumor growth and reduces cancer recurrence in lab models
A research team has developed an approach to significantly reduce the risk of cancer recurrence and metastasis after surgery, by targeting both bulk cancer cells and the elusive cancer stem cells (CSC...
phys.org
September 25, 2025 at 1:25 AM
labwaggoner.bsky.social
A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models @naturecomms.bsky.social
www.nature.com/articles/s41...
March 3, 2025 at 3:25 AM
atranscendedman.bsky.social
Chinese researchers developed a new SARS-CoV-2 vaccine using outer membrane vesicles (OMVs) to enhance immunity.

The OMV-RBD nanovaccine triggered strong antibody and T-cell responses in mice via both intranasal and intramuscular routes.

jnanobiotechnology.biomedcentral.com/articles/10....
RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2 - Journal of Nanobiotechnology
Background Since the emergence of SARS-CoV-2, the causative agent of COVID-19, the global health landscape has confronted an unprecedented and formidable challenge. The SARS-CoV-2 receptor-binding dom...
jnanobiotechnology.biomedcentral.com
February 9, 2025 at 2:37 PM
sciences.skyfleet.blue
Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy
Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy
Next-generation thermostable multiepitope nanovaccine generates mucosal immunity and regulates PD-1/PD-L1 axis within the dendritic cell (DC)-T cell interface, coordinating CD4 and CD8 T-cell immunities and activating robust neutralizing antibody responses against SARS-CoV-2. Abstract The first approved vaccines for human use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are nanotechnology-based. Although they are modular, rapidly produced, and can reduce disease severity, the currently available vaccines are restricted in preventing infection, stressing the global demand for novel preventive vaccine technologies. Bearing this in mind, we set out to develop a flexible nanovaccine platform for nasal administration to induce mucosal immunity, which is fundamental for optimal protection against respiratory virus infection. The next-generation multiepitope nanovaccines co-deliver immunogenic peptides, selected by an immunoinformatic workflow, along with adjuvants and regulators of the PD-L1 expression. As a case study, we focused on SARS-CoV-2 peptides as relevant antigens to validate the approach. This platform can evoke both local and systemic cellular- and humoral-specific responses against SARS-CoV-2. This led to the secretion of immunoglobulin A (IgA), capable of neutralizing SARS-CoV-2, including variants of concern, following a heterologous immunization strategy. Considering the limitations of the required cold chain distribution for current nanotechnology-based vaccines, it is shown that the lyophilized nanovaccine is stable for long-term at room temperature and retains its in vivo efficacy upon reconstitution. This makes it particularly relevant for developing countries and offers a modular system adaptable to future viral threats.
onlinelibrary.wiley.com
August 9, 2024 at 10:16 AM
nizet.bsky.social
Celebratory lab luncheon for Hervé Besançon, who completed his SNSF 🇨🇭 postdoc with us here in La Jolla. In addition to his good cheer and Swiss panache, he made fantastic contributions to our nanovaccine studies

Expert by birthright, Hervé taught proper fondue technique at the chocolate fountain
October 30, 2025 at 1:56 AM
captaincalliope.at
So in a sense, they fingerprinted covid and this nanovaccine passes the fingerprint around like a wanted poster?
December 10, 2024 at 4:40 AM
covid19disease.bsky.social
China's Wuhan lab accused of Covid leak develops intranasal vaccine to protect against all forms of coronavirus

Wuhan lab researchers have created a nanovaccine offering universal protection against all COVID variants and future mutations.

www.deccanherald.com/world/chinas...
China's Wuhan lab accused of Covid leak develops intranasal vaccine to protect against all forms of coronavirus
www.deccanherald.com
September 15, 2024 at 2:55 AM
warosintfella.bsky.social
@richardhirschs1
NASAL VACCINES FOR AIRBORNE VIRUSES ARE THE FUTURE.
We are exposed to viruses this way, and our immune systems are best adapted to deal with infections this way.
We are making giant leaps in nasal delivery vaccines both for INFECTIONS and CANCERS.
Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy
Next-generation thermostable multiepitope nanovaccine generates mucosal immunity and regulates PD-1/PD-L1 axis within the dendritic cell (DC)-T cell interface, coordinating CD4 and CD8 T-cell immunit...
onlinelibrary.wiley.com
January 3, 2025 at 4:54 PM
edrybicki.bsky.social
Nanovaccine halts tumor growth and reduces cancer recurrence in lab models
Nanovaccine halts tumor growth and reduces cancer recurrence in lab models
A research team has developed an approach to significantly reduce the risk of cancer recurrence and metastasis after surgery, by targeting both bulk cancer cells and the elusive cancer stem cells (CSCs) responsible for relapse.
phys.org
September 25, 2025 at 8:30 AM
Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection
www.nature.com/articles/s41...
Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection - npj Vaccines
npj Vaccines - Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection
www.nature.com
June 1, 2024 at 1:07 AM
sailorrooscout.bsky.social
nanoparticles. Eventually, their nano-vaccine proved effective against all major variants of SARS-CoV-2, including Beta, Delta, Omicron, etc. Nano-vaccines can offer a significant advantage over existing vaccines because it is needle-free and administered as a nasal spray. This eliminates the need
Figure 2. Nanoplatform physicochemical characterization. A) Schematic representation of the nanovaccine (NV). B) Representative image of spherical empty nanoparticle (NP) by transmission electron microscopy (TEM), scale bar = 200 nm. C) Representative image of spherical empty NP by scanning electron microscopy (SEM), scale bar = 1 µm. D) Atomic force microscopy (AFM) images show the spherical shape of NP with a slight roughness surface, scale bar = 200 nm. E,F) Hydrodynamic diameter measurements by dynamic light scattering (DLS) of empty NP (NP w/o immunogens) and NV (NP entrapping one SARS-CoV-2-RBD peptide and the two TLR ligands) over time. E) Lyophilized empty NP and NV stored at 24 °C. F) Empty NP and NV in suspension were stored at 4 and 24 °C. Data represent mean ± s.d. (n =  5). G) Cell viability of bone marrow-derived dendritic cells (BMDC) after incubation with NP for 44 h by XTT. Data represent mean ± s.d. (a representative graph of 2 independent experiments demonstrating the same trend). All group comparisons were non-significant (NS) by the One-way ANOVA test. H) In vivo safety timeline, C57BL/6J mice. I,J) Assessment of motor function. I) RotaRod test. The motor learning of C57BL/6 male mice was analyzed in a five-lane accelerating RotaRod. J) Open field test. The distance traveled by C57BL/6 male mice during a 15-min video recording was analyzed using EthoVision 13XT software. Data represent mean ± s.e.m., N = 10 mice. All group comparisons were NS by the One-way ANOVA test. K,L) Blood test, N = 5 mice. All comparisons between the groups were NS by the One-way ANOVA test. Data represent mean ± s.e.m. Whisker charts show minimum and maximum values. K) Blood chemistry panel, and L) Blood hematology panel (CBC panel). Figure 3. Nanovaccine -8 (NV-8) elicited robust receptor-binding domain (RDB)-specific T- and B-cell responses. A) Immunization scheme of C57BL/6J mice timeline. B) SARS-CoV-2 RBD-peptide, and C) RBD-specific IgG antibody titers determined by Enzyme-Linked Immunosorbent Assay (ELISA) on day 35. Box and whisker plots represent the mean, min, and max, N = 5 (PBS) or 12 (NV), unpaired t-test. D-H) Cellular response. D) Uniform manifold approximation and projection (UMAP) plot of lymphocytes (CD45+ CD3+ cells) colored by Interferon gamma (IFN-γ), Tumor necrosis factor-alpha (TNF-α), Interleukin-2 (IL-2), and IL-4 expression. E) Frequency of antigen-specific CD4+ T cells producing T helper 1 (Th1) cytokines, IFN-γ, IL-2, and TNF-α; F) Th2 cytokine, IL-4; and G) CD8+ T cells producing IFN-γ and IL-2 cytokines were evaluated 1 week after the second vaccination (day 28) in 6 h antigen-stimulated splenocytes. H) Frequency of Tfh retrieved from (1) spleen and (2) inguinal lymph nodes of mice on day 28. Data represent mean ± s.e.m., N = 5 mice, one-way ANOVA followed by Tukey's multiple comparisons test. I) Frequency of Tfr cells retrieved from (1) spleen and (2) inguinal lymph nodes of mice on day 28. Data represent mean ± s.e.m., N = 5 mice, one-way ANOVA followed by Tukey's multiple comparisons test. J) ELISpot representative images of IFN-γ spot forming cells among splenocytes after ex vivo restimulation with peptides 14 and 15 on day 28. Each condition was repeated five times. K) IFN-γ spot forming units (SFU). Data represent mean ± s.e.m., N = 5 mice, one-way ANOVA followed by Tukey's multiple comparisons test. L-M) Frequency of effector memory T cells (CD4+ and CD8+) evaluated 1 week after IV administration of MHCI/II-binding peptides and the adjuvants (CpG and Poly(I:C)). N) SARS-CoV-2 RBD-peptides IgG levels were evaluated on day 101 by ELISA (dilution 1:500). The number of mice per group: PBS/Empty NP = 9, Free = 10, and NV-8 = 8, mean ± s.e.m. Figure 4. Co-delivery of receptor-binding domain (RBD)-peptides, toll-like receptor (TLR) ligands, and siRNA against Programmed death-ligand 1 (PD-L1) (siPD-L1 NV-8) increases NV-8 neutralizing-antibody responses. A) Schematic representation of siPD-L1 NV-8 B) PD-L1 and PD-1 mRNA levels from spleen, 55 h post siNC NV-8 (negative control of scramble siRNA) or siPD-L1 NV-8 immunization. mRNA levels measured by qRT-PCR. Data represent mean ± s.e.m., N = 5 mice, unpaired t-test. C) Immunization scheme of C57BL/6J mice timeline. SARS-CoV-2 RBD-peptides, and RBD-specific IgG D,E), IgG1 F), and IgG2a G) antibody titers determined by ELISA. Box and whiskers represent the mean, min, and max, N = 5 mice per group, unpaired t-test. H,I) PD-L1, and PD-1 mRNA levels, from spleens, on day 28. mRNA levels measured by qRT-PCR. Data represent mean ± s.e.m., N = 5 mice, one-way ANOVA followed by Dunnett's multiple comparisons test. J) Frequency of germinal center (GC) B cells detected by flow cytometry on day 28. Data represent mean ± s.e.m., N = 5 mice, one-way ANOVA followed by Tuke's multiple comparisons test. NT50 in serum against SARS-CoV-2 RBD WT K), Delta (Δ) L), and Omicron BA.1.1 (Ο) M) in mice immunized with NV-8, siNC NV-8, and siPD-L1 NV-8 using surrogate virus neutralization test. Data represent mean ± s.e.m., N = 5 mice, one-way ANOVA followed by Dunnett's multiple comparisons test. Figure 5. Intranasal siPD-L1 NV-8-booster elicited robust mucosal immunity. A) Immunization scheme of C57BL/6J mice timeline. B,C) Mucosal-cellular response determined by flow cytometry on day 28. Frequency of tissue-resident T cells (TRM) (CD4+ and CD8+) D,C), and antibody-secreting B cells E) in the nasal mucosa. Data represent mean ± s.e.m., N = 5 mice (subcutaneous (SC) booster), and 10 (intranasal (IN) booster), one-way ANOVA followed by Tuke's multiple comparisons test. E–K) Mucosal-humoral response. E) Frequency of immunoglobulin (Ig) IgA-B cells in nasal mucosa on day 28. F,G) SARS-CoV-2 receptor-binding domain (RBD)-peptides and RBD-specific secretory immunoglobulin A (SIgA) titers in bronchoalveolar lavage fluid (BALF) determined by ELISA. Box and whiskers represent the mean, min, and max, N = 5 mice per group, unpaired t-test. H) Neutralizing antibody titers (NT50) against SARS-CoV-2 in BALF determined by surrogate virus neutralization test. Data represent mean ± s.e.m., N = 5 mice, unpaired t-test. SARS-CoV-2 RBD-peptides and RBD-specific IgA titers I,J), and IgG in serum K,L) determined by ELISA. Box and whiskers represent the mean, min, and max, N = 5 mice per group, unpaired t-test. M–P) Comparison between siPD-L1 NV-8 versus mRNA vaccine. M,N) Cellular response. The frequency of antigen-specific CD4+ T cells producing T helper 1 (Th1) cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) M) was evaluated one week after the intranasal booster (day 28) and after stimulation with RBD-peptides or spike protein for 6 h. Cytokine production (IFN-γ and TNF-α) was also evaluated on CD8+ T cells N). O) Frequency of germinal center B cells, Tfh, and Tfr cells retrieved from mice on day 28. Data represent mean ± s.e.m., N = 5 mice, unpaired t-test. P) SARS-CoV-2 RBD IgG antibody titers determined on day 35 by ELISA. Box and whisker plots represent the mean, min, and max, N = 5, unpaired t-test.
December 9, 2024 at 5:06 PM
aggregate-journal.bsky.social
A Versatile Polymer-Based In Situ Nanovaccine to Boost Cancer Immunotherapy
DOI: https://doi.org/10.1002/agt2.70353
TOC Image
June 3, 2026 at 10:45 AM
cp-cellrepmed.bsky.social
Online now: Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy
Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy
Lei et al. screen Lactococcus lactis OMVs (Lac-OMVs) and develop a metabolically engineered NAD+-Lac-OMV nanovaccine with potent tissue-repair therapeutic effects. NAD+-Lac-OMVs sequentially activate dendritic cells by membrane components and reprogram inflammatory macrophages for anti-inflammation and bone repair by interior nicotinamide metabolites.
dlvr.it
June 4, 2026 at 7:20 PM
teteisu.bsky.social
O Butantã está desenvolvendo uma vacina intranasal contra o SARS-CoV-2. Os testes pré-clínicos são promissores.
Na torcida para que haja não só dinheiro para ir adiante como para os resultados sejam confirmados.
Produção de IgA é a única forma de bloquear a infecção.

www.nature.com/articles/s41...
An innovative nasal nanovaccine against SARS-CoV-2 induces systemic and upper airway immunity controlling viral replication - npj Vaccines
npj Vaccines - An innovative nasal nanovaccine against SARS-CoV-2 induces systemic and upper airway immunity controlling viral replication
www.nature.com
April 8, 2026 at 4:30 PM
lettersfromtim.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...
Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy
Next-generation thermostable multiepitope nanovaccine generates mucosal immunity and regulates PD-1/PD-L1 axis within the dendritic cell (DC)-T cell interface, coordinating CD4 and CD8 T-cell immunit...
onlinelibrary.wiley.com
November 22, 2024 at 12:56 AM
materchemfront.rsc.org
🔔 Research article by Wei Gu 𝘦𝘵 𝘢𝘭.

A high-entropy nanozyme-based photothermal-adjuvant in situ nanovaccine for potentiated tumor immunotherapy

🔗 doi.org/10.1039/d5qm...

#Nanozymes #Immunotherapy #Nanovaccines #Photothermal
September 15, 2026 at 4:44 AM
iastateresearch.bsky.social
New Iowa State PIRS project: designing peptide-based adjuvants from endogenous proteins to power personalized nanovaccines.

Led by Jing Wang with collaborators Balaji Narasimhan & Michael Wannemuehler at the Nanovaccine Institute. Details: go.iastate.edu/ODBYVA

#vaccine #immunology
Innovating Tomorrow's Vaccines. What if future vaccines could be personalized to different immune systems? Meet the research team working to shape that future. Balaji Narasimhan, Jing Wang, and Michael Wannemuehler.
March 12, 2026 at 9:41 PM
atranscendedman.bsky.social
Chengdu scientists tested a dual-ligand mRNA nanovaccine in mice.

By cloaking particles with a CD47 peptide to evade macrophages and mannose to target dendritic cells, it drove strong, durable Th1-biased immunity against SARS-CoV-2.

www.cell.com/cell-biomate...
A precision-engineered dendritic cell-targeted mRNA nanovaccine for enhanced antiviral immunity
Effective delivery is a critical challenge for mRNA vaccines. We engineered a precision-engineered lipid-like nanoparticle (LLN) platform with a dual-ligand strategy: a CD47-derived peptide minimizes ...
www.cell.com
August 21, 2025 at 2:40 PM
bionewscentral.com
A novel #immunotherapy employs a #nanovaccine that targets both bulk #TumorCells and #CancerStemCells to reduce the risk of post‑surgical #recurrence and #metastasis.
#CancerImmunotherapy #CancerVaccine
Novel nanovaccine halts tumor growth and reduces cancer recurrence – BioNews Central
A novel immunotherapy employs a nanovaccine that targets both bulk tumor cells and cancer stem cells to reduce the risk of post‑surgical recurrence and metastasis. ...
sbee.link
September 25, 2025 at 2:46 AM
thatcovidlife.bsky.social
Advanced Science: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy: ABSTRACT

The first approved vaccines for human use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are nanotechnology-based. Although… #ThatCovidLife #CovidIsNotOver
Advanced Science: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
ABSTRACT The first approved vaccines for human use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are nanotechnology-based. Although they are modular, rapidly produced, and can reduce disease severity, the currently available vacc...
dlvr.it
December 9, 2024 at 4:15 PM
zenbia.bsky.social
While Trump plays his little games with allies, in China...
Chinese vaccine shows promise in stopping plaque build-up in arteries
In mice trial, experimental nanovaccine found to reduce development of condition that can lead to blood clots, stroke and heart attacks.
www.scmp.com
March 11, 2025 at 4:36 PM
sigtrans-sttt.bsky.social
Researchers develop a peptide-loaded hybrid membrane #Nanovaccine that enables personalized #Immunotherapy for #HPV-related cervical diseases, generating targeted immune responses and offering a promising therapeutic strategy.
#STTT #OpenAccess: doi.org/10.1038/s413...
Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases
June 8, 2026 at 1:45 PM
cp-cellrepmed.bsky.social
Online now: Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy
Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy
Lei et al. screen Lactococcus lactis OMVs (Lac-OMVs) and develop a metabolically engineered NAD+-Lac-OMV nanovaccine with potent tissue-repair therapeutic effects. NAD+-Lac-OMVs sequentially activate dendritic cells by membrane components and reprogram inflammatory macrophages for anti-inflammation and bone repair by interior nicotinamide metabolites.
dlvr.it
June 18, 2026 at 7:19 PM
rridrobot.bsky.social
RRID:AB_2107436 from @proteintech.bsky.social was used by authors in their Cell Reports Medicine paper. Thanks for making your methods matter! #ReproducibleResearch #RRID #STMpublishing
Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy
Read the full paper: Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy
doi.org
June 5, 2026 at 7:01 AM